 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other May 13 Calls Today's Calls |
| Call Details | |||
| JAZZ PHARMACEUTICALS INC Earnings Conference Call (Q1 2008) Tue, May 13, 2008, 5:00 pm Eastern
| |||
| About JAZZ PHARMACEUTICALS INC (NasdaqGM:JAZZ) | |||
| Jazz Pharmaceuticals, Inc. focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its marketed and approved products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Luvox CR, an extended release formulation of fluvoxaminefor, which is a selective serotonin reuptake inhibitor for the treatment of obsessive compulsive disorder and social anxiety disorder; and Antizol, an antidote for suspected or confirmed ethylene glycol or methanol poisonings in humans. The company’s clinical development pipeline comprises JZP-6, a phase III clinical trial product for the treatment of fibromyalgia; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder that is in phase II clinical trial; JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients, which is in phase II clinical trial; and JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome that is in phase I/II clinical trial. Jazz Pharmaceuticals has a product license agreement with Solvay Pharmaceuticals, Inc. to market Luvox CR and Luvox in the United States; and with GlaxoSmithKline to purchase worldwide rights to the active pharmaceutical ingredient in JZP-4. The company was founded in 2003 and is headquartered in Palo Alto, California. | |||
More Info: | |||
